19 Indehaveren af markedsføringstilladelsen blev bedt om at revidere afsnit 4. 5 Interaktion med andre lægemidler og andre former for interaktion, fordi der ikke forventes nogen farmakokinetiske interaktioner med dette stof, da det ikke metaboliseres, og to tredjedele af den indtagne dosis udskilles uændret i urinen.
The MAH was asked to revise section 4.5 Interaction with other medicinal products, as no pharmacokinetic interactions are awaited with this substance, since it is not metabolised and two third of the ingested dose are eliminated unchanged in urine.